Endocrinology

National cohort study finds semaglutide tied to reduced depression, anxiety, and self-harm risk in patients with diabetes and comorbid mental illness.

A metabolic polygenic risk score built from 20 traits and more than 8.5 million individuals outperformed existing disease-prediction models.

This episode features discussion around 3 recent announcements from Novo Nordisk, Eli Lilly, and Structure Therapeutics.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new phase 3 data, in this week’s essential news roundup.

FDA clears setmelanotide for acquired hypothalamic obesity for ages 4 years and older, delivering 15.8% BMI drop in TRANSCEND.

The first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist delivered superior A1C reduction and weight loss at 40 weeks in people with type 2 diabetes.

ATTD 2026 reveals AI “digital twins,” next-gen closed-loop pumps, and sensors that boost time-in-range and ease diabetes management.

The MiniMed Flex is a discreet, smartphone-controlled insulin pump that is roughly the size of 2 stacked insulin vials.

New data show tegoprubart enabled insulin independence and strong glycemic control in adults with long-standing type 1 diabetes undergoing islet transplantation.

Data from the ACCESS II trial, ACCESS extension study, and a body composition study provide an early look at efficacy and safety data of a new investigational oral GLP-1.

Bialo discusses her perspective on the importance of T1D screening and its capacity to reduce the risk of disease progression and eventual complications later in life.

Tozzi and Wallach discuss ways to omit artificial sweeteners and added sugars from children’s diets and minimize risk for T2D and MASLD later in life.

Alexander discusses his recent study comparing 61 trials of 4 main GLP-1 RAs, highlighting their increased efficacy for weight loss in female patients.

The approval comes after the FDA requested GSK submit an sNDA for leucovorin for the treatment of CFD-FOLR1.

Budini discusses his recent study investigating the trajectory of weight regain after GLP-1 cessation, given current high discontinuation rates.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2026.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline results from the TRIUMPH-4 trial, demonstrating retatrutide's efficacy in promoting weight loss.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recently published trial results and what they mean for Eli Lilly’s newest GLP-1 molecule.

This World Obesity Day, catch up on major paradigm shifts in the diagnosis, discussion, and treatment of obesity, one of the world’s most devastating chronic diseases.

Catch up with FDA decisions, key trial results, podcast updates, and more.

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

The long-acting growth hormone is now indicated for children aged 2.5 years and older with Idiopathic Short Stature, born Small for Gestational Age, or Noonan Syndrome.

Parent company Eli Lilly has released full data from ACHIEVE-3, indicating superior weight loss and A1C reductions with orforglipron 12 mg and 36 mg.

The FDA has approved proprietary desmopressin oral solution formulation ET-600 for the treatment of central diabetes insipidus in children.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recent approval and what it means for Wegovy 7.2 mg in the US.